Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | UBE2N | P61088 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.43 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3064294 | 0.80 | MAPT (0.67) | ALDH1A1MAPTHSD17B10ALOX15KDM4E | |
| SCHEMBL935581 | 0.80 | ALDH1A1 (0.67) | ALDH1A1MAPTHSD17B10ALOX15KDM4E | |
| SCHEMBL1539779 | 0.78 | MAPT (0.64) | ALDH1A1MAPTHSD17B10ALOX15KDM4E | |
| SCHEMBL1539813 | 0.78 | MAPT (0.64) | ALDH1A1MAPTHSD17B10ALOX15KDM4E | |
| SCHEMBL1539819 | 0.78 | ALDH1A1 (0.64) | ALDH1A1MAPTHSD17B10ALOX15KDM4E | |
| SCHEMBL6441223 | 0.76 | ALDH1A1 (0.61) | ALDH1A1MAPTHSD17B10ALOX15KDM4E | |
| SCHEMBL27587795 | 0.75 | ALDH1A1 (0.59) | ALDH1A1MAPTHSD17B10ALOX15KDM4E | |
| SCHEMBL3090550 | 0.74 | MAPT (0.58) | ALDH1A1MAPTHSD17B10ALOX15KDM4E | |
| SCHEMBL1778210 | 0.74 | KDM4E (0.58) | ALDH1A1MAPTHSD17B10ALOX15KDM4E | |
| SCHEMBL12681373 | 0.73 | ALDH1A1 (0.55) | ALDH1A1MAPTHSD17B10ALOX15KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007073855-A1 | USE OF ADENOSINE A1 RECEPTOR AGONISTS FOR THE PROTECTION OF RENAL CELLS AGAINST TOXIC EFFECTS CAUSED BY AMINOGLYCOSIDES DURING TREATMENT OF INFECTIOUS DISEASES | BAYER HEALTHCARE AG (DE) | 2007-07-05 | — | — | WO | claimed |
| EP-3782622-A1 | ADENOSINE A2B RECEPTOR AGONIST FOR THE TREATMENT OF MUSCULOSKELETAL CONDITIONS | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2021-02-24 | — | — | EP | disclosed |
| WO-2018153899-A1 | SELECTIVE PARTIAL ADENOSINE A1 RECEPTOR AGONISTS IN COMBINATION WITH SOLUBLE GUANYLYL CYCLASE (SGC) STIMULATORS AND/OR ACTIVATORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-08-30 | — | — | WO | disclosed |
| WO-2018153898-A1 | SELECTIVE PARTIAL ADENOSINE A1 RECEPTOR AGONISTS IN COMBINATION WITH MINERALOCORTICOID RECEPTOR ANTAGONISTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-08-30 | — | — | WO | disclosed |
| WO-2018153897-A1 | SELECTIVE PARTIAL ADENOSINE A1 RECEPTOR AGONISTS IN COMBINATION WITH HCN CHANNEL BLOCKERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-08-30 | — | — | WO | disclosed |
| WO-2018153895-A1 | SELECTIVE PARTIAL ADENOSINE A1 RECEPTOR AGONISTS IN COMBINATION WITH A NEUTRAL ENDOPEPTIDASE INHIBITOR AND/OR AN ANGIOTENSIN II RECEPTOR ANTAGONIST | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-08-30 | — | — | WO | disclosed |
| WO-2018153900-A1 | SELECTIVE PARTIAL ADENOSINE A1 RECEPTOR AGONISTS IN COMBINATION WITH SGLT-2 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2018-08-30 | — | — | WO | disclosed |
| US-20160311812-A1 | ADENOSINE A1 AGONISTS AS MEDICAMENTS FOR KIDNEY DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-27 | — | — | US | disclosed |
| EP-3079696-A1 | ADENOSINE A1 AGONISTS AS MEDICAMENTS AGAINST RENAL DISEASES | Bayer Pharma Aktiengesellschaft (DE) | 2016-10-19 | — | — | EP | disclosed |
| EP-2274299-B1 | HETEROARYL-SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF FOR TREATMENT OF CARDIOVASCULAR DISEASES | BAYER IP GMBH (DE) | 2016-06-15 | — | — | EP | disclosed |
| WO-2005034950-A1 | PYRIDOTHIOPHENE COMPOUNDS | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2005-04-21 | — | — | WO | disclosed |
| US-20040176417-A1 | Substituted 2-thio-3, 5-dicyano-4-phenyl-6-aminopyridines and their use as adenosine receptor-selective ligands | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-09-09 | — | — | US | disclosed |
| US-20040176417-A1 | Substituted 2-thio-3, 5-dicyano-4-phenyl-6-aminopyridines and their use as adenosine receptor-selective ligands | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-09-09 | — | — | US | disclosed |
| US-20040102626-A1 | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines with adenosine receptor-binding activity and their use cardiovascular preparations | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-05-27 | — | — | US | disclosed |
| EP-1417173-A1 | SUBSTITUTED 2-THIO-3, 5-DICYANO-4-PHENYL-6-AMINOPYRIDINES AND THEIR USE AS ADENOSINE RECEPTOR-SELECTIVE LIGANDS | Bayer HealthCare AG (DE) | 2004-05-12 | — | — | EP | disclosed |
| US-6586441-B2 | 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders | HOFFMAN-LA ROCHE INC. | 2003-07-01 | — | — | US | disclosed |
| WO-2003008384-A1 | SUBSTITUTED 2-THIO-3, 5-DICYANO-4-PHENYL-6-AMINOPYRIDINES AND THEIR USE AS ADENOSINE RECEPTOR-SELECTIVE LIGANDS | BAYER HEALTHCARE AG (DE) | 2003-01-30 | — | — | WO | disclosed |
| EP-1261327-A2 | ADENOSINE RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2002-12-04 | — | — | EP | disclosed |
| US-20010027196-A1 | Adenosine receptor ligands and their use in the treatment of disease | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-04 | — | — | US | disclosed |
| WO-2001062233-A2 | ADENOSINE RECEPTOR MODULATORS | F. HOFFMANN LA ROCHE AG (CH) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027196-A1 | Adenosine receptor ligands and their use in the treatment of disease | ADORA2A, ADORA2B, ADORA1 | ALDH1A1 534/4885MAPT 1878/4885HSD17B10 3742/4885 |
| US-20040102626-A1 | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines with adenosine receptor-binding activity and their use cardiovascular preparations | ADORA1, ADORA2A, ADORA3 | ALDH1A1 361/4885MAPT 4422/4885HSD17B10 3820/4885 |
| US-20040176417-A1 | Substituted 2-thio-3, 5-dicyano-4-phenyl-6-aminopyridines and their use as adenosine receptor-selective ligands | ADORA1, ADORA3, ADORA2A | ALDH1A1 476/4885MAPT 3697/4885HSD17B10 4556/4885 |
| US-20160311812-A1 | ADENOSINE A1 AGONISTS AS MEDICAMENTS FOR KIDNEY DISORDERS | ADORA1, ADORA2A, ADORA2B | ALDH1A1 336/4885MAPT 4795/4885HSD17B10 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.